Prevention of acute organ rejection in patients after allogeneic kidney, heart, and liver transplantation in combination therapy with cyclosporine and corticosteroids.
Composition and form of release
Cellsept is produced in capsules and tablets coated with a film that dissolves in the intestine. The active ingredient is mycophenolate mofetil.
Cellsept is used in combination therapy with cyclosporins and corticosteroids for:
prevention of acute rejection after kidney transplantation or treatment of organ rejection refractory to therapy in patients who have undergone allogeneic transplantation;
improving the quality of survival and prevention of acute transplant rejection and survival of patients after a homogeneous heart transplant;
prevention of acute organ rejection in patients who have undergone homogeneous liver transplantation.
Cellsept is not prescribed for patients who suffer from mycophenolate mofetil intolerance and a hereditary deficiency of hypoxanthine-guanine phosphoribosyl transferase.
It is not prescribed for children with a body area of less than 1.5 square meters and for patients who have not reached the age of 14, since there is no information on the safety of using the drug in therapy after heart, kidney or liver transplantation in patients of this age group.
Care should be taken to prescribe Sellsept to patients suffering from chronic diseases of the digestive system.
The drug is not prescribed in conjunction with azathioprine and is used with caution as part of a complex treatment together with tacrolimus, sirolimus and drugs that affect the hepatic-intestinal circulation.
Application during pregnancy and lactation
Cellsept is categorically contraindicated in pregnant and lactating women. The drug can be used in the treatment of women of fertile age only when using reliable methods of contraception.
Method of administration and dosage
Cellcept capsules and tablets are used only for oral administration. To prevent the development of kidney rejection, treatment begins in the first 72 hours after organ transplantation. Adult patients and children take 1 g of the drug 2 times a day.
To prevent the occurrence of rejection of a homogeneous heart or liver, treatment begins in the first five days after transplantation. The drug is taken 1.5 g 2 times per knock.
If, in the process of taking Cellsept, the patient develops neutropenia, then his reception is temporarily stopped until the laboratory parameters are normalized.
Patients with severe renal failure are prohibited from taking Cellsept more than 3 g per day.
When Cellsept is taken in high doses, there is an increased development of side symptoms.
Taking Cellsept with corticosteroids or cyclosporins may cause vomiting, diarrhea, leukopenia, anemia, sepsis, and an increased risk of opportunistic infections.
When taking Cellsept, some patients experience asthenia, peritonitis, abdominal pain, edema of the extremities, fever, ascites, impaired wound healing, leukocytosis, headaches, arrhythmias, heart failure, acidosis, pleural or pericardial effusion, weight gain, anorexia, herpes , acne, drowsiness, facial swelling and hair loss.
Storage conditions and periods
Cellcept should be stored in places that are protected from light and moisture. Duration of storage of Cellsept is 3 years.